Testing a New Skin Barrier Product Against Petrolatum in Adults With Skin Problems
Tests a new skin barrier product against petrolatum in adults with dry, irritated skin.
Plain-language title generated from the registry record
Registry title: Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction
Key facts
- Where
- Makati City, PhilippinesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with mild skin barrier problems, such as mild to moderate atopic dermatitis, mild to moderate plaque psoriasis, contact dermatitis or dry skin. It compares a new skin cream with petrolatum.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Mild skin barrier dysfunction: mild to moderate atopic dermatitis (SCORAD ≤ 50, and/or not currently needing topical corticosteroids or immunomodulators), mild to moderate chronic plaque psoriasis (body surface area involved ≤3% to 10%), contact dermatitis, or seasonal or clearly visible dry skin.
- Earlier treatment
- Cannot have used corticosteroids, calcineurin inhibitors, biologics or phototherapy within 2 weeks.
Main reasons for not taking part
- Severe atopic dermatitis or psoriasis needing systemic or high-potency topical treatment
- Open wounds or signs of a secondary infection at the test sites
- Pregnant or breastfeeding women
- Multiple nevi, tattoos or dense body hair in the test areas
- Weakened body (debilitated or immunocompromised), or known or suspected allergy to the products or petrolatum
Read by machine on 9 November 2026.
Where in Philippines
- VMV Skin Research Center & ClinicsMakati City, PhilippinesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Makati Medical Center
- Trial code
- NCT07183423
- Record updated
- 19 September 2025
- Original description
The goal of this clinical trial is to learn if a novel barrier topical product works to treat barrier dysfunction in adults. It will also learn about the safety of the novel barrier topical product. The main questions it aims to answer are:Read full original descriptionShow less
A Pilot Double-Blind Randomized Controlled Trial on the Efficacy and Safety of a Novel Skin Barrier Product Versus Petrolatum in Individuals With Skin Barrier Dysfunction
The goal of this clinical trial is to learn if a novel barrier topical product works to treat barrier dysfunction in adults. It will also learn about the safety of the novel barrier topical product. The main questions it aims to answer are:
Does the novel barrier topical product improve skin hydration, skin sebum, redness, and pigmentation? Does it improve subjective dryness and itch? Researchers will compare the novel barrier topical product to petrolatum (a gold standard occlusive barrier repair agent) to see how they are comparable in treating skin barrier dysfunction.
Participants will:
Apply the novel barrier topical product or petrolatum twice a day for 28 days Visit the clinic once a week for checkups and tests Keep a diary of their application of the assigned product
Inclusion: Clinical diagnosis of mild skin barrier dysfunction, including:; Mild to moderate atopic dermatitis, defined as SCORAD ≤ 50, and/or not currently requiring topical corticosteroids or immunomodulators; Mild to moderate chronic plaque psoriasis, defined as total body surface area (BSA) involved: ≤3% to 10%; Contact dermatitis; Seasonal xerosis or clinically evident skin dryness; Symmetrical or bilateral test areas available (volar forearm); Willing and able to provide informed consent and adhere to study procedures.
Exclusion: Use of corticosteroids, calcineurin inhibitors, biologics, or phototherapy within 2 weeks; Failure to meet any of the above inclusion criteria; Open wounds or evidence of secondary infection at test sites; Known or suspected hypersensitivity to the interventional product (or its ingredients) or petrolatum; Refusal or failure to comply with the schedule of visits at the test site; Severe atopic dermatitis or psoriasis requiring systemic or high-potency topical treatment; Pregnant or breastfeeding women; Multiple nevi, tattoos, dense body hair in the test areas; Debilitated or immunocompromised subjects.